NeuroLucent Overview

  • Founded
  • 2016
Founded
  • Status
  • Private
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $4M
Latest Deal Amount
  • Investors
  • 4

NeuroLucent General Information

Description

Developer of ryanodine receptor drugs designed to treat Alzheimer's disease. The company's drugs stabilizes dysregulated calcium signaling within brain cells in patients with early Alzheimer's or mild cognitive impairment, enabling patients to restore healthy neuronal signaling and keep synaptic health and memory function intact.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Primary Office
  • 1261 Oak Knoll Drive
  • Lake Forest, IL 60045
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

NeuroLucent Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Grant 29-Aug-2018 $4M Completed Startup
1. Accelerator/Incubator 20-Sep-2016 Completed Startup
To view NeuroLucent’s complete valuation and funding history, request access »

NeuroLucent Executive Team (5)

Name Title Board Seat Contact Info
Grace Stutzmann Ph.D Co-Founder, Chief Scientific Officer & Principal Researcher
John Buolamwini Ph.D Co-Founder and Medicinal Chemist
Robert Marr Ph.D Co-Founder and Molecular Biologist
William Kohlbrenner Ph.D President & Chief Executive Officer
Glenn Gottfried Co-Founder & Chairman
To view NeuroLucent’s complete executive team members history, request access »

NeuroLucent Board Members (1)

Name Representing Role Since
Glenn Gottfried Self Co-Founder & Chairman 000 0000
To view NeuroLucent’s complete board members history, request access »

NeuroLucent Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Alzheimers Drug Discovery Foundation Not-For-Profit Venture Capital 000 0000 000000 0
National Institute On Aging Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
SmartHealth Catalyzer Accelerator/Incubator 000 0000 000000 0
To view NeuroLucent’s complete investors history, request access »